Bagsværd, Denmark, 4 February 2026 – Novo Nordisk A/S has filed its Annual Report 2025 on Form 20-F for the…
Bagsværd, Denmark, 31 January 2026 – Thomas Rantzau, employee representative on the Board of Directors since 2018, has decided to pursue…
Compared with tirzepatide, Wegovy® (semaglutide 2.4 mg) showed a significant 57% greater reduction in the risk of heart attack, stroke…
Bagsværd, Denmark, 15 August 2025 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved an…
New FRONTIER5 data show that a direct switch to investigational Mim8 (denecimig) prophylaxis treatment from emicizumab, without the need for…
Data presented simultaneously at the American Diabetes Association’s® 85th Scientific Sessions, showed mean weight reduction in the highest range of…